Skip to main content
Offering
Offering
Integrated Biologics
Integrated Biologics
Expression Technologies
Expression Technologies
GS Xceed® Gene Expression System
GS piggyBac® Transposon Technology
GS Effex® Cell Line
GS Discovery® Transient Expression
bYlok® Bispecific Pairing Technology
XS Technologies®
Technical Support
Early Derisking and Optimization
Early Derisking and Optimization
Developability Assessment
Manufacturability Assessment
Antibody Humanization and Deimmunization
Protein Engineering
Potency Assessment
Immunogenicity / Immunotoxicity Assessment
Rapid Host Screen and Early Protein Expression
Non-GMP Manufacture
Epibase® in vitro and in silico Screening
Mammalian Biopharmaceutical Services
Mammalian Biopharmaceutical Services
Ibex® Design mAbs DNA-to-IND Program
Ibex® Design Bispecifics DNA-to-IND Program
Ibex® Design Scaffolds and other Recombinant Proteins
Cell Line Development
Tailored License Application Program
Process Development
Analytical Development
Drug Substance Manufacturing
Parenteral Drug Product Services
Parenteral Drug Product Services
Clinical Technology Transfers
Biologics Formulatability
Product Formulation Development
Analytics
Process Development
Biologics Special Services
Drug Product Manufacture
Large-scale Manufacturing Expansion
Biologics Regulatory Services
Knowledge Center
Advanced Synthesis
Advanced Synthesis
Small Molecules
Small Molecules
Drug Substance/API Services
Drug Substance/API Services
Early Phase Small Molecule Development Services
API Support for Early Phase Development
AI-Enabled Route Scouting Service
Solid Form Drug Services
PBPK Modeling Services
Pharmaceutical Method Development
Commercial API Manufacturing Services
Highly Potent API Technologies
Highly Potent API Technologies
HPAPI Handling and Development
HPAPI Manufacturing | Low & High Potency
ADC Clinical and Commercial Manufacturing
ADC Payload Product Development
Particle Engineering
Particle Engineering
Solid Dispersion Technology
Bioavailability Enhancement
Spray-Dried Dispersion Technology
Micronization and Jet Milling
Hot Melt Extrusion
Drug Product
Drug Product
SimpliFiH® Solutions
Drug Product Technologies
Drug Product Technologies
Specialized Drug Product Development
Micro-dosing for Early Human Clinical Studies
Clinical Trial Material Manufacture, Supply
Clinical Bottling, Labelling and Supply
Formulation and Development
Design and Preformulation Development
Drug Development Workflow & Pharmaceutical Process Optimization
Pediatric Drug Product Development
Inhalation Formulation Development
Integrated Offerings
Regulatory Affairs CMC Services
Regulatory Affairs CMC Services
CMC Development Services | CMC Regulatory Submissions
Bioconjugates Services
Bioconjugates Services
Early Development Bioconjugates | ADCs
ADC Drug Substance Manufacturing
Pharmaceutical, ADC Analytical Services
Targeting Agent and Carrier Protein
ADC Process Development
Ibex® Design ADC, DNA-to-IND Program
Knowledge Center
Specialized Modalities
Specialized Modalities
Cell & Gene
Cell & Gene
Process Development
cGMP Manufacturing
Allogeneic
Autologous
Viral Vectors
Exosomes
Cocoon® Platform
Microbial
Microbial
Microbial Strain Development
Process Development
Drug Substance Manufacturing
Analytical Development
mRNA/LNP
mRNA/LNP
Process Development
Analytical Services
mRNA Manufacturing
Lipid Nanoparticles Encapsulation
Bioscience Products
Knowledge Center
Knowledge Center
Company
Company
About Us
About Us
Our One Lonza Strategy
Our Leadership
Our Leadership
Executive Committee
Board of Directors
Board Committees
Our History
Our Locations
News and Media
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
A View On - Lonza Podcast
Journalist Inquiries
Investor Relations
Investor Relations
Shareholders and Stock Information
Shareholders and Stock Information
Consensus and Analysts
Bond Investors and Credit Information
Investor FAQ
Share Buyback
Agenda and Events
Reporting and Presentations
Corporate Governance
Ethics and Compliance
Investor Inquiries and Feedback
Sustainability
Sustainability
Environment
People and Society
Compliance and Integrity
Responsible Sourcing
Global Quality
Careers
Careers
Welcome to Lonza
Life at Lonza
Employee Benefits
Early Career Opportunities
Inclusion, Diversity and Belonging
Join Our Talent Community
Contact
Search
Cancel
Home
Knowledge Center
Making it happen: the road to commercial-scale
31 Aug 2018
Making it happen: the road to commercial-scale
1h webinar focused on CT technology platforms including autologous, 3D bioreactors, iPSCs.
You may also be interested in:
Allogeneic
Autologous
iPSCs
Analytical Development
First Name
Last Name
Business Email
Company Name
Country
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas (the)
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia (Plurinational State of)
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory (the)
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands (the)
Central African Republic (the)
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands (the)
Colombia
Comoros (the)
Congo (the)
Congo (the Democratic Republic of the)
Cook Islands (the)
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curacao
Cyprus
Czechia
Denmark
Djibouti
Dominica
Dominican Republic (the)
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Falkland Islands (the) [Malvinas]
Faroe Islands (the)
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories (the)
Gabon
Gambia (the)
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (the)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran (Islamic Republic of)
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea (the Democratic People's Republic of)
Korea (the Republic of)
Kuwait
Kyrgyzstan
Lao People's Democratic Republic (the)
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands (the)
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia (Federated States of)
Moldova (the Republic of)
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands (the)
New Caledonia
New Zealand
Nicaragua
Niger (the)
Nigeria
Niue
Norfolk Island
North Macedonia
Northern Mariana Islands (the)
Norway
Oman
Pakistan
Palau
Palestine, State of
Panama
Papua New Guinea
Paraguay
Peru
Philippines (the)
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation (the)
Rwanda
Saint Barthelemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan (the)
Suriname
Svalbard and Jan Mayen
Sweden
Switzerland
Syrian Arab Republic (the)
Taiwan (Province of China)
Tajikistan
Tanzania, the United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands (the)
Tuvalu
Uganda
United Kingdom
Ukraine
United Arab Emirates (the)
United States Minor Outlying Islands (the)
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela (Bolivarian Republic of)
Viet Nam
Virgin Islands (British)
Virgin Islands (U.S.)
Global
Wallis and Futuna
Western Sahara*
Yemen
Zambia
Zimbabwe
State
Alaska
Alabama
Arkansas
American Samoa
Arizona
California
Colorado
Connecticut
District of Columbia
Delaware
Florida
Georgia
Guam
Hawaii
Iowa
Idaho
Illinois
Indiana
Kansas
Kentucky
Louisiana
Massachusetts
Maryland
Maine
Michigan
Minnesota
Missouri
Northern Mariana Islands
Mississippi
Montana
North Carolina
North Dakota
Nebraska
New Hampshire
New Jersey
New Mexico
Nevada
New York
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
U.S. Minor Outlying Islands (cf. separate entry UM)
Utah
Virginia
Virgin Islands of the U.S.
Vermont
Washington
Wisconsin
West Virginia
Wyoming
Join our community to receive tailored insights and resources. You can unsubscribe at any time.
By clicking "Access Content" you agree to our
Legal Disclaimer
and the
Lonza Privacy and Cookies Policy
.
Loading...
Latest briefing from the Knowledge Center
White paper
Bringing novel ADC formats into the clinic: Process development for antibody-oligonucleotide...
Bioconjugates are no longer just for cancer therapies. This paper reveals how innovative...
Webinar (on-demand)
Commercialization of CAR-T therapy in New Zealand: clinical insights & scalable manufacturing
Revolutionizing CAR T Therapy: Insights from New Zealand’s Breakthrough Webinar Discover how...
Article
From Molecule to Medicine: overcoming development challenges with the right CDMO partner
Publication
Systematic Development of a Detergent Toolbox as an Alternative to Triton X-100
In biomanufacturing, detergents are essential for inactivating enveloped viruses during protein...
White paper
Transferring your cell line with confidence
This white paper explores flexible, data-driven strategies that help streamline biologics...
Article
Partnering for Innovation: Lonza Supports a UK Biotech Developing an Entirely New Modality with...
Epsilogen CEO, Tim Wilson, shares his company’s experience finding the right CDMO partner, willing...
Article
Lonza’s Expertise and Technical Appetite Help Epsilogen Bring the First IgE Therapeutic into the...
Tim Wilson, CEO of London-based biotech Epsilogen, discusses the company’s journey to develop a...
Article
Q&A: Getting it right first time - the importance of early expression vector design
In this interview, Lonza’s Dr. Peter O’Callaghan (Senior Director, Head of Expression System...
Webinar (on-demand)
Future-proofing gene therapy: scalable AAV solutions and non-viral innovations
As gene therapy moves toward broader commercialization, the pressure to streamline production and...
Technical/Service brief
GS Gene Expression System: reliability today, innovation for tomorrow
Emerging and small biotechs play a critical role in driving scientific innovation, often advancing...
Article
The Evolving Landscape of ADC Analytical Development
Previous
Next
Cookie Settings
|
Terms and Conditions
|
Legal Disclaimer
|
Privacy Policy
|
Accessibility